I MAB (IMAB) Opciones

IMAB.......................https://stockcharts.com/h-sc/ui?s=IMAB&p=W&b=5&g=0&id=p86431144783

IMAB.................................https://stockcharts.com/h-sc/ui?s=IMAB&p=W&b=5&g=0&id=p86431144783

IMAB under $2

IMAB under $2

IMAB under $2

Imab $1.80 golden cross https://schrts.co/CNBigxhc

I-Mab Price Target Maintained With a $6.00/Share by Needham
Mentioned: IMAB

Ratings actions from Benzinga: https://www.benzinga.com/quote/IMAB/analyst-ratings

(END) Dow Jones Newswires

April 12, 2024 06:15 ET (10:15 GMT)

IMAB 10Q due 4/3

IMAB under $2=

IMAB under $2

IMAB under $2

IMAB
This is a long-term deal. The China divestiture had to be done to facilitate the future sale of the company. There would be too many Chinese entities to satisfy and hence introduce uncertainty in a future sale. The loss of the Jumpcan deal is a negative because the numbers were spelled out. I will feel much more comfortable about IMAB after they get a Giva or a Uli licensing deal. Combined, based on prior deals for similar drugs would be worth $1B+. It is likely they will have to pay out $30M to the non participants. The $80M from Hangzhou will take years to collect. But, there is one point that has not been addressed. That is the pricing of drugs in China. The Chinese government is notorious for asking for discounts. The pricing of drugs in the USA is better. IMAB has shifted its focus to drugs in a market where they will get much better pricing. The unknown is will IMAB get a deal for Giva, or Uli ?

2-3 minutes before the close over 500k shares were dumped. Same exercise happened to several Chinese stocks.

Based on the Astra Zeneca agreement with KYM for their Claudin 18.2 drug, and the Antengene agreement with Calithera for their CD73 inhibitor drug, I estimate that IMAB has potential contracts worth $1.25B+.

Why doesn't IMAB license Givasgtomig and Ulilidimab? I estimate that the milestone payments would be at least $500M. The share would be at least $5.

From the 20-F report

On July 16, 2022, I-Mab Hangzhou entered into a definitive financing agreement with a group of domestic investors in China to raise approximately US$46 million (in RMB equivalent). On the same date, we, through our wholly-owned subsidiary, entered into a shareholders agreement with I-Mab Hangzhou and other domestic investors in I-Mab Hangzhou named therein (the “I-Mab Hangzhou Shareholders Agreement”). Upon the occurrence of certain triggering events as specified in the I-Mab Hangzhou Shareholders Agreement, including but not limited to I-Mab Hangzhou’s failure to accomplish certain public offering condition, we may be obligated to repurchase the equity held by other domestic investors in cash or in our stocks in the period beyond 12 months.

In the most recent reporting period, Decheng Capital purchased 4 million shares of IMAB.

The stock has bounced off $1.80 two times within a month.

Not a surprise to see a pull back from the +50% rise last week. A large order came in at the end of yesterday. Nevertheless, it is disappointing to see the slide. It could fall back to $1.28. Mr. Kannan will be at a conference on 11/14. I think the China approvals will send the stock past $3 next year. The company will be sold by the end of 2025.

IMAB climbing the charts tracking the $3s. Check it out soon.

mb

IMAB under $2